NDA 021029 · Merck Sharp Dohme
Temodar
Temozolomide · Oral · Alkylating Drug
NovelAccelerated approvalPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 14, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Aug 11, 1999
Approved uses
6
Original approval plus efficacy supplements
Registered trials
1,139
125 Phase 3, 153 recruiting
FAERS reports
21,320
17,250 serious, 4,502 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 20, 2026.
TEMODAR is an alkylating drug indicated for the treatment of adults with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma. ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 ) 1.1 Newly Diagnosed Glioblastoma TEMODAR is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMODAR is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma.
Mechanism: Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to DNA alkylation, mainly at the O 6 and N 7 positions of guanine, which causes DNA double strand breaks and results in programmed cell death.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 14, 2023 Supplement 37 · Efficacy LabelLetterReview
- Sep 14, 2023 Supplement 38 · Efficacy LabelLetterReview
- Sep 14, 2023 Supplement 36 · Efficacy LabelLetterReview
- Mar 15, 2005 Supplement 8 · Efficacy · priority review LetterLabel
- Mar 11, 2003 Supplement 5 · Efficacy · priority review Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
- Aug 11, 1999 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewLetter
6 products under this application
- TEMODAR · TEMOZOLOMIDE 140MG · CAPSULE, ORAL · Discontinued · TE AB
- TEMODAR · TEMOZOLOMIDE 100MG · CAPSULE, ORAL · Discontinued · TE AB
- TEMODAR · TEMOZOLOMIDE 5MG · CAPSULE, ORAL · Discontinued · TE AB
- TEMODAR · TEMOZOLOMIDE 180MG · CAPSULE, ORAL · Discontinued · TE AB
- TEMODAR · TEMOZOLOMIDE 250MG · CAPSULE, ORAL · Discontinued · TE AB
- TEMODAR · TEMOZOLOMIDE 20MG · CAPSULE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Temozolomide" as an intervention, any sponsor and status, largest first.
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPivotal-lookingRecruiting
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT03970447 · 2,250 participants (planned) · Start Jul 30, 2019 · Primary completion Jun 2028
Drug: Temozolomide; Lomustine and 8 more · For: Glioblastoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 63 sites in all
- FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcomaPivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT04625907 · 1,672 participants (planned) · Start Sep 17, 2020 · Primary completion Jun 2030
Drug: Irinotecan; Actinomycin D and 7 more · For: Rhabdomyosarcoma
Sites: Brisbane, Australia; Camperdown, Australia; Clayton, Australia · 128 sites in all
- Pan Tumor Rollover StudyRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03899155 · 1,500 participants (planned) · Start Aug 9, 2019 · Primary completion Aug 25, 2029
Drug: Nivolumab; Ipilimumab and 17 more · For: Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Lynwood, California · 410 sites in all
- Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaPivotal-lookingCompleted
Radiation Therapy Oncology GroupResearch network
NCT00304031 · 1,173 participants · Start Jan 2006 · Primary completion Feb 2011
Drug: Concurrent temozolomide; 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle and 1 more · For: Brain and Central Nervous System Tumors
Sites: Fairbanks, Alaska; Phoenix, Arizona; Scottsdale, Arizona · 351 sites in all
- Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed GlioblastomaPivotal-lookingCompleted
King Faisal Specialist Hospital & Research CenterAcademic, hospital or other
NCT01364064 · 1,153 participants · Start Jan 2007 · Primary completion Jun 2008
Drug: TMZ · For: Glioblastoma
Institut du Cancer de Montpellier - Val d'AurelleAcademic, hospital or other
NCT04025541 · 992 participants (planned) · Start May 29, 2018 · Primary completion May 29, 2029
Drug: Blood sampling; Blood sampling C3 and 7 more · For: Cancer; Breast Cancer; Sarcoma and 3 more
Sites: Montpellier, France · 2 sites in all
- A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed GlioblastomaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00943826 · 921 participants · Start Jun 29, 2009 · Primary completion Feb 28, 2013
Drug: Bevacizumab; Temozolomide and 1 more · For: Glioblastoma
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 133 sites in all
- Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00091572 · 859 participants · Start Oct 20, 2004 · Primary completion Dec 31, 2007
Drug: Temozolomide; Dacarbazine · For: Melanoma
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- disease progression1,895
- off label use1,833
- death1,811
- thrombocytopenia1,592
- product use in unapproved indication1,474
- nausea1,332
- drug ineffective1,270
- fatigue1,050
- neutropenia1,041
- vomiting991
- malignant neoplasm progression944
- febrile neutropenia839
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 149 |
| 2005 | 291 |
| 2006 | 304 |
| 2007 | 579 |
| 2008 | 747 |
| 2009 | 441 |
| 2010 | 403 |
| 2011 | 462 |
| 2012 | 736 |
| 2013 | 671 |
| 2014 | 617 |
| 2015 | 779 |
| 2016 | 852 |
| 2017 | 1,041 |
| 2018 | 1,205 |
| 2019 | 1,170 |
| 2020 | 1,483 |
| 2021 | 1,560 |
| 2022 | 1,994 |
| 2023 | 1,746 |
| 2024 | 1,527 |
| 2025 | 1,524 |
| 2026 | 1,039 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Stupp R, Mason WP, van den Bent MJ, et al. · N Engl J Med 2005 · Clinical Trial, Clinical Trial, Phase III
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R, Taillibert S, Kanner A, et al. · JAMA 2017 · Clinical Trial, Phase III, Comparative Study
- Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Perry JR, Laperriere N, O'Callaghan CJ, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL, Graham NT, Catalano PJ, et al. · J Clin Oncol 2023 · Clinical Trial, Phase II, Multicenter Study
- Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
van den Bent MJ, Tesileanu CMS, Wick W, et al. · Lancet Oncol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Gilbert MR, Dignam JJ, Armstrong TS, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.